Use of emicizumab in Venezuelan haemophilia A patients: Preliminary report

被引：0
|
作者：
Boadas, Apsara [1 ]
Ruiz-Saez, Arlette [1 ]
Aponte, Laura [2 ]
Echenagucia, Marion [3 ]
Lugo, Ines [4 ]
Tersek, Yraida [5 ]
机构：
[1] Dept Invest & Docencia, Caracas, Venezuela
[2] Natl Hemophilia Ctr Venezuela Banco Municipal San, Caracas, Venezuela
[3] Lab Hemostasia Banco Municipal Sangre DC, Caracas, Venezuela
[4] Hosp Rafael Tobias, Barcelona, Venezuela
[5] Hosp Cent San Felipe, San Felipe, Estado Yaracuy, Venezuela
来源：
HAEMOPHILIA | 2022年 / 28卷
关键词：
emicizumab; haemophilia A patients; prophylaxis;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PP-68 (116
引用
收藏
页码：51 / 52
页数：2
相关论文
共 50 条
  • [41] Low dose emicizumab prophylaxis in haemophilia a patients: A pilot study from India
    Bansal, Shweta
    Donners, Anouk A. M. T.
    Fischer, Kathelijn
    Kshirsagar, Shrinath
    Rangarajan, Savita
    Phadke, Varsha
    Mhatre, Shrutika
    Sontate, Bharati
    D'silva, Magdelene
    Ansari, Shahana
    Shetty, Shrimati
    HAEMOPHILIA, 2023, 29 (03) : 931 - 934
  • [42] Emicizumab dose capping in obese patients with Haemophilia A: Early outcomes at a single centre
    Krumb, Evelien
    Lambert, Catherine
    Hermans, Cedric
    HAEMOPHILIA, 2022, 28 (06) : E245 - E247
  • [43] Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors
    Roman, Maria Teresa Alvarez
    Kragh, Nana
    Guyot, Patricia
    Wilson, Amanda
    Wojciechowski, Piotr
    Margas, Wojciech
    Wdowiak, Marlena
    Santagostino, Elena
    Arnaud, Alix
    ADVANCES IN THERAPY, 2025, 42 (01) : 442 - 455
  • [44] Beliefs, opinions and impact of emicizumab in haemophilia A patients: A National US Survey Study
    Al-Samkari, Hanny
    Croteau, Stacy E.
    HAEMOPHILIA, 2021, 27 (02) : E270 - E273
  • [45] Blue toe syndrome, severe haemophilia A and emicizumab
    Cardoso, Patricia Santos Resende
    da Silva, Camila Beatriz Pereira Gomes
    de Abreu, Eliabe Silva
    Oliveira, Andrea Goncalves
    Pereira, Isabel Figueiredo de Magalhaes
    Navarro, Tulio Pinho
    Rezende, Suely Meireles
    HAEMOPHILIA, 2024, 30 (01) : 241 - 244
  • [46] Persistent inhibitor in acquired haemophilia A: A case for emicizumab?
    Ganslmeier, Mira
    Pekrul, Isabell
    Heinrich, Daniel Alexander
    Angstwurm, Matthias
    Spannagl, Michael
    Moehnle, Patrick
    HAEMOPHILIA, 2021, 27 (04) : E502 - E505
  • [47] Outcomes of emicizumab-KXWH use in persons with haemophilia A at moi teaching and referral hospital
    Oburah, M. E.
    Njuguna, F.
    Greist, A.
    Kilach, C.
    Ramani, R.
    Ndemo, K.
    Njuguna, C.
    Aliwa, E.
    HAEMOPHILIA, 2024, 30 : 80 - 80
  • [48] Immune tolerance induction in paediatric patients with haemophilia A and inhibitors receiving emicizumab prophylaxis
    Batsuli, Glaivy
    Zimowski, Karen L.
    Tickle, Kelly
    Meeks, Shannon L.
    Sidonio, Robert F., Jr.
    HAEMOPHILIA, 2019, 25 (05) : 789 - 796
  • [49] Real-world cost estimates of initiating emicizumab in US patients with haemophilia A
    Samelson-Jones, Benjamin J.
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Raffini, Leslie
    HAEMOPHILIA, 2021, 27 (04) : 591 - 598
  • [50] COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB FOR THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A WITH INHIBITORS IN PORTUGAL
    Soares, V
    Freitas, L. A.
    Cafe, A.
    VALUE IN HEALTH, 2019, 22 : S905 - S905
12345